Business Context and Reporting Period
This Form 8-K reports on the 2022 Annual Meeting of Stockholders held by Zentalis Pharmaceuticals, Inc. on June 8, 2022. The filing details the voting results for director elections, auditor ratification, and executive compensation advisory votes.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
A total of 39,276,592 shares were present or represented by proxy, representing approximately 86% of outstanding common stock. The following proposals were approved:
- Director Elections: Cam S. Gallagher and Karan S. Takhar were elected as Class II Directors to serve until the 2025 Annual Meeting.
- Auditor Ratification: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2022.
- Executive Compensation: Stockholders approved the advisory vote on the compensation of named executive officers.
- Compensation Vote Frequency: Stockholders recommended that future advisory votes on executive compensation be held every year.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The Board of Directors has determined to hold annual advisory votes on executive compensation based on the stockholder recommendation.
Key Facts for Investor Verification
- Verify the specific vote counts for director elections, noting significant "Votes Withheld" for both nominees (approx. 8 million each).
- Confirm the ratification of Ernst & Young LLP as the auditor for the 2022 fiscal year.
- Note the stockholder preference for annual "say-on-pay" votes rather than biennial or triennial cycles.
- Review the definitive proxy statement filed on April 28, 2022, for detailed background on the proposals.